GLP‑1 drugs cut heart attacks and strokes by 13%
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- GLP-1 receptor agonists reduced the risk of major adverse cardiovascular events by about 13% in 11 outcome trials with an average follow‑up of nearly three years.
- Anglia Ruskin University researchers reviewed data from more than 90,000 participants in large international clinical trials to assess long‑term cardiovascular outcomes of GLP‑1 drugs.
- The review found no meaningful increase in serious safety risks such as severe hypoglycaemia or acute pancreatitis compared with placebo, though gastrointestinal side effects remained more common.
- High‑risk patients (those with obesity, type 2 diabetes, or existing heart disease) experienced the strongest reduction in heart attacks, strokes, and premature death.
- Dr. Simon Cork said the cardiovascular benefits were consistent across different GLP‑1 drugs, trial designs, and patient groups, supporting broader use in clinical practice and health policy.
- Semaglutide, liraglutide, and dulaglutide are the widely used GLP‑1 receptor agonists highlighted in the analysis, underscoring that the benefits apply across multiple drug formulations.
Why it matters: Patients with obesity, type 2 diabetes or existing heart disease gain a roughly 13% reduction in heart attacks, strokes and premature death, while health systems gain lower cardiovascular mortality without new safety concerns, as the review found no increase in severe hypoglycaemia or pancreatitis.
